Company Overview and News

 
KLCI tracks regional gains, select blue chips lift

2018-09-14 theedgemarkets
KUALA LUMPUR (Sept 14): The FBM KLCI edged up in early trade this morning, lifted by select blue chips, tracking gains at most regional markets.
4634 7084 1023 5260 7022 GEBHF GBTKF CIMDF

 
Most slide on trade war jitters, headed for weekly decline

2018-09-07 theedgemarkets
(Sept 7): Most Southeast Asian stock markets fell on Friday in line with broader Asia, as investors feared a new round of Sino-U.S. tariffs, while lingering economic woes in emerging markets also hit sentiment.
GEBHF

 
KLCI remains under pressure, struggles to defend 1,800-level

2018-09-07 theedgemarkets
KUALA LUMPUR (Sept 7): The FBM KLCI remained under pressure at midday break today and struggled to defend its 1,800-point level.
HLFBF UPBMF 7036 1082 7113 TPGVF BATS 4162 0096 7087 5168 2089 5014 7123 TGLVY 3026 3867 1368 MYPRY 2836 GEBHF 3719 HRGHY

 
KLCI pares gains, dips below 1,800-level as regional markets slip

2018-09-07 theedgemarkets
KUALA LUMPUR (Sept 7): The FBM KLCI pared some of its gains at mid-morning today amid some chopping trading as regional markets slipped.
4065 7036 BATS 4162 0096 7087 5014 7123 4863 3867 5819 MYPRY MYTEF 2836 BSMAF GEBHF 3719 1818

 
Tenaga, Public Bank lift KLCI in early trade

2018-09-07 theedgemarkets
KUALA LUMPUR (Sept 7): The FBM KLCI edged higher in early trade this morning, lifted by gains at index-linked heavyweights.
PBLOF 1295 6033 4588 PNADF 5347 TNABY 5819 2836 TNABF PNAGF GEBHF 3719

 
Stock market could be volatile in the months ahead, says CIMB Research

2018-09-05 theedgemarkets
KUALA LUMPUR (Sept 5): CIMB IB Research said August was a good month for the KLCI as the market ended on a positive note despite disappointing 2Q GDP growth and a soft corporate earnings season but said the stock market could be volatile in the months ahead.
5246 GEBHF 7277

 
Trend is bullish but may pull back

2018-09-05 theedgemarkets
The FBM KLCI climbed to its highest level in three months last week in a mixed global market on higher crude and crude palm oil prices. However, the last two trading days were directionless as the market started to take profits after the index rose to a three-month high. The FBM KLCI increased 0.6% in a week to 1,819.66 points last Thursday. Not much movement in the market this week and the index closed at 1,812.
HLFBF 4863 5819 1082 MYTEF GEBHF

 
Genting Bhd shares fall to lowest in eight weeks

2018-09-03 theedgemarkets
KUALA LUMPUR (Sept 3): Genting Bhd shares fell 2 percent, more than any full-day drop since June 12, as Malaysia's benchmark index declined.
GEBHF

 
Trading ideas: Econpile, Destini, Sentoria, Dayang

2018-08-30 thestar.com.my
KUALA LUMPUR: Econpile Holdings Bhd , Destini Bhd , Sentoria Group Bhd and Dayang Enterprise Holdings Bhd are among the stocks to watch today, according to JF Apex Research.
4634 GMALY BSTHY 4715 GMALF 5253 5141 5213 2771 GEBHF

 
Genting first half earnings retreat

2018-08-30 thestar.com.my
Revenue and Ebitda from Resorts World Sentosa for H1’18 were comparable with that of the previous year, with growth in both the gaming and non-gaming businesses.
GMALY G13 4715 GMALF GIGNF GEBHF GIGNY

 
Genting’s 2Q net profit down 16%, declares 8.5 sen dividend

2018-08-29 theedgemarkets
KUALA LUMPUR (Aug 29): Genting Bhd’s net profit for the second quarter of its financial year ending Dec 31, 2018 (2QFY18) slipped 16% year-on-year to RM383.52 million from RM454.14 million, dragged by reduced earnings from its overseas leisure and hospitality businesses, as well as lower plantation and power contributions.
GEBHF

 
Economist: Govt to review several subsidy systems next year

2018-08-26 malaymail
KUALA LUMPUR, Aug 26 ― The government is expected to review several subsidy systems by next year, says Maybank Investment Bank Bhd (Maybank IB) Group Chief Economist Suhaimi Ilias.
0166 7293 1015 AMMHF 1163 GEBHF

 
KLCI pares gains as decliners overtake advancers

2018-08-10 theedgemarkets
KUALA LUMPUR (Aug 10): The FBM KLCI pared some of its gains at midday today as decliners overtook advancers, tracking the sentiment at most regional markets.
SPMXF UPBMF 7036 5681 BATS 4162 7765 5015 2089 5014 0131 6033 2593 2852 0143 5029 PNADF SPMXY 3883 0026 MYPRY PNAGF GEBHF

 
Genting’s S’pore unit 2Q profit in line with forecasts

2018-08-07 theedgemarkets
Genting Bhd (Aug 6, RM8.69) Retain outperform with an unchanged target price of RM11.50: Genting Singapore plc, a 52.7% subsidiary of Genting Bhd, reported a net profit of S$177.6 million (RM724.61 million) for the second quarter of financial year 2018 (2QFY18), posting a year-on-year (y-o-y) growth of 23.9%. The results were in line with our and consensus full-year forecasts for Genting Singapore.
G13 GIGNF GEBHF GIGNY

 
Billion Ringgit Club 2018: The Edge Billion Ringgit Club is back for the ninth year

2018-08-03 theedgemarkets
THE Edge Media Group and partners are celebrating Corporate Malaysia’s best-performing companies and top responsible organisations at The Edge Billion Ringgit Club (BRC) gala dinner for the ninth straight year.
7084 MLYBY SPMXF MLYNF 8664 AMMHF 5246 1155 1015 SPMXY 5347 3026 TNABY 6888 AXXTF TNABF GEBHF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 00B1VXJL8